Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 10, Issue 2, Pages 214-219Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1600-6143.2009.02955.x
Keywords
Dendritic cells; T cells; tolerance; transplantation
Categories
Funding
- National Institutes of Health [R01 AI060994, R01 AI067541, P01AI81678, U01 AI051698]
- Roche Organ Transplantation Research Foundation
Ask authors/readers for more resources
Although well-recognized for their sentinel role and, when activated, their immunostimulatory function, bone marrow-derived dendritic cells (DC) possess inherent tolerogenic (tol) ability. Under quiescent conditions, these cells maintain central and peripheral self tolerance. When appropriately conditioned, in vitro or in vivo, they inhibit innate and adaptive immunity to foreign antigens, including memory T-cell responses. This suppressive function is mediated by various mechanisms, including the expansion and induction of antigen-specific regulatory T cells. Extensive experience in rodent models and recent work in nonhuman primates, indicate the potential of pharmacologically-modified, tol DC (tolDC) to regulate alloimmunity in vivo and to promote lasting, alloantigen-specific T-cell unresponsiveness and transplant survival. While there are many questions yet to be addressed concerning the functional biology of tolDC in humans, these cells offer considerable potential as natural, safe and antigen-specific regulators for long-term control of the outcome of organ and hematopoietic cell transplantation. This minireview surveys recent findings that enhance understanding of the functional biology and therapeutic application of tolDC, with special reference to transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available